BRIEF-Adaptimmune Therapeutics says FDA grants orphan drug designation to its t-cell therapy

* U.S. Food and drug administration grants orphan drug designation to adaptimmune's t-cell therapy targeting ny-eso for treatment of soft tissue sarcoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.